Royalty Pharma G&A decreased by 2.9% to $159.49M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 44.1%, from $110.71M to $159.49M. Over 4 years (FY 2021 to FY 2025), G&A shows an upward trend with a 33.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Rising G&A as a percentage of revenue may indicate organizational bloat, while stability suggests effective cost management.
Detailed definition
General and administrative expenses cover the overhead costs of running the business, including executive salaries, lega...
Peer comparison
Standard operating expense category; used to assess administrative leverage.
Metric ID:
general_and_administrativeHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $44.92M | $48.59M | $46.16M | $51.54M | $51.84M | $50.69M | $73.23M | $85.70M | $47.63M | $57.23M | $59.19M | $57.65M | $54.71M | $56.72M | $67.59M | $110.71M | $179.77M | $118.73M | $164.27M | $159.49M |
| QoQ Change | — | +8.2% | -5.0% | +11.7% | +0.6% | -2.2% | +44.5% | +17.0% | -44.4% | +20.2% | +3.4% | -2.6% | -5.1% | +3.7% | +19.2% | +63.8% | +62.4% | -34.0% | +38.4% | -2.9% |
| YoY Change | — | — | — | — | +15.4% | +4.3% | +58.6% | +66.3% | -8.1% | +12.9% | -19.2% | -32.7% | +14.9% | -0.9% | +14.2% | +92.0% | +228.6% | +109.3% | +143.0% | +44.1% |
Range$44.92M – $179.77M
CAGR+30.6%
Avg YoY Growth+46.4%
Median YoY Growth+15.1%
G&A at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's g&a?
- Royalty Pharma (RPRX) reported g&a of $159.49M in Q1 2026.
- How has Royalty Pharma's g&a changed year-over-year?
- Royalty Pharma's g&a increased by 44.1% year-over-year, from $110.71M to $159.49M.
- What is the long-term trend for Royalty Pharma's g&a?
- Over 4 years (2021 to 2025), Royalty Pharma's g&a has grown at a 33.1% compound annual growth rate (CAGR), from $182.83M to $573.48M.
- What does g&a mean?
- The overhead costs required to manage and support the company's operations.